.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC53_TegafurCombinations.TegafurCombinations .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC53_TegafurCombinations.TegafurCombinations| name: | TegafurCombinations |
| ATC code: | L01BC53 | route: | oral |
| n-compartments | 2 |
Tegafur, in combinations (ATC L01BC53), is an oral chemotherapeutic agent used mainly in conjunction with other agents such as uracil or gimeracil and oteracil (as S-1 formulation) for the treatment of various solid tumors, especially gastric and colorectal cancer. It is a prodrug of 5-fluorouracil (5-FU) that is bioactivated in the body, and these combinations are approved and still in clinical use for several cancer indications.
Pharmacokinetic parameters reported for adult cancer patients (mixed sex, typical age range 40-70 years) receiving S-1 (tegafur/gimeracil/oteracil) orally.
Kobuchi, S, et al., & Sakaeda, T (2018). Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 123 452–458. DOI:10.1016/j.ejps.2018.08.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30077713
Zuo, L, et al., & Chen, R (2024). Establishment and validation of a population pharmacokinetic model for apatinib in patients with tumors. BMC cancer 24(1) 1346–None. DOI:10.1186/s12885-024-13118-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39487410
Shirao, K, et al., & Abbruzzese, JL (2004). Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(17) 3466–3474. DOI:10.1200/JCO.2004.05.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15277535